The Medical Letter on Drugs and Therapeutics
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance)
April 18, 2022 (Issue: 1648)The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart...more
- Empagliflozin (Jardiance) for heart failure with reduced ejection fraction. Med Lett Drugs Ther 2021; 63:171.
- Dapagliflozin (Farxiga) – a new indication for heart failure. Med Lett Drugs Ther 2020; 62:102.
- SD Anker et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385:1451.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2022. Reprinted with permission by First Databank, Inc. All rights reserved. ©2022. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.